Form D · Biotechnology
Carterra, Inc.
Salt Lake City, UT · CIK 0001541582
Offering snapshot reported Apr 24, 2024 · SEC filing
- Reported sold
- $5M Offering amount: $5M
- Investors reported
- 15 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 7, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 24, 2024 | Initial | $5,000,000 | No comparison | 15 | SEC filing |
| Dec 22, 2020 | Amendment | $8,090,487 | $2,090,489vs Oct 23, 2020 | 37 | SEC filing |
| Oct 23, 2020 | Initial | $5,999,998 | No comparison | 1 | SEC filing |
| Jan 3, 2020 | Initial | $5,999,997 | No comparison | 30 | SEC filing |
| Sep 14, 2018 | Initial | $4,473,062 | No comparison | 2 | SEC filing |
| Sep 8, 2016 | Amendment | $10,299,651 | $0vs Aug 18, 2016 | 19 | SEC filing |
| Aug 18, 2016 | Initial | $10,299,651 | No comparison | 19 | SEC filing |
| Jan 7, 2014 | Amendment | $482,631 | $0vs Jan 3, 2014 | 8 | SEC filing |
| Jan 3, 2014 | Initial | $482,631 | No comparison | 8 | SEC filing |
| Feb 7, 2012 | Initial | $200,000 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-511416
Source: Form D, filed Apr 24, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jack Ball | Director |
| Josh Eckman | Director |
| Janel Fillinger | Executive |
| Bruce Gale | Director, Executive |
| Alexander Herzick | Director |
| Joe Keegan | Director |
| John Lillig | Director |
| Kirk Ririe | Director |
| Gary Sams | Director |
| Jim Smith | Director |
| Bill Tew | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
825 North 300 West, Suite C309
Salt Lake City, UT, 84103
Salt Lake City, UT, 84103